Ciprofloxacin in the Treatment of Chronic Osteomyelitis in Adults

Trujillo, I Zavala; Valladares, G; Nava, Arnulfo

doi:10.2165/00003495-199300453-00202

Cited by 6 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently great interest has been shown in the use of fluoroquinolones, because they can be taken by the oral route, are well tolerated for long-regimen treatments, have a good bone distribution and a rapid efficacy on many gram positive and negative bacteria. [2,9,13] . The efficacy of these treatments ranged from 65% [14] to 95% [15] Oral quinolones are commonly used in the treatment of osteomyelitis [7,[13][14][15][16][17][18][19][20][21][22] .…”

Section: Introductionmentioning

confidence: 99%

“…[2,9,13] . The efficacy of these treatments ranged from 65% [14] to 95% [15] Oral quinolones are commonly used in the treatment of osteomyelitis [7,[13][14][15][16][17][18][19][20][21][22] . Moreover Greenberg et al [20] claimed that they are safe and effective if they are given for a prolonged course of treatment for infections caused by susceptible gram-positive as well as gram-negative organisms and in combination with adequate surgical debridement.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Standard versus Specific Therapy for Chronic Osteomyelitis Treatment

Ingianni¹,

Lampis²,

Laconi³

et al. 2007

American J. of Infectious Diseases

View full text Add to dashboard Cite

58 patients with chronic osteomyelitis were treated either with a standard therapy or with a specific targeted therapy based on the antibiogram assay. Standard therapy was performed by a 15-day course of a parenteral cephalosporin (usually ceftriaxone) in combination with an aminoglycoside (e.g. netilmicin), followed by oral therapy with a fluoroquinolone (generally ciprofloxacin) for 1 to 3 months; specific therapy largely varied depending on the antibiogram response. The results indicated that no significant differences were found between the patients who received standard therapy (95.5 % cured) and those who received a specific therapy (93.5 % cured), after a one year follow-up. It can be concluded that a short-term combined parenteral-oral standard therapy, indicated in all those cases where antibiotic therapy must be started before obtaining the laboratory response, or when a clear and definite identification of the microorganisms involved in the infection is not possible, can be as efficient as an antibiogram-guided therapy in the treatment of chronic osteomyelitis.

show abstract